Scientific research team

One expert of "national talent project" was independently cultivated and three experts of "national talent project" were introduced. Shandong Province "national talent project" expert workstation was awarded by provincial science and technology department.

• 

  Hong Tao (chief academic consultant)

  He is an academician of Chinese Academy of engineering, member of the Third World Academy of Sciences (Twas), winner of the National May 1st Labor Medal, chief expert of China Center for Disease Control and prevention, and the main pioneer of biomedical electron microscopy technology and prion research in China. In 1955, he graduated from Shandong Medical College; in 1960, he got his doctor's degree from Virology Research Institute of Romanian Academy of Sciences, and returned to China in the same year to engage in medical virology research, specializing in virus morphology and medical ultrastructure. The first discovery of human group B rotavirus (adult diarrhea rotavirus ADRV), the first discovery of the morphology of hemorrhagic fever with nephrotic syndrome virus, solved the attribution of the virus, and obtained world validation and recognition. Together with Academician Huang Zhenxiang, he founded the Chinese society of medical viruses and the Chinese Journal of experimental and clinical virology. He has published more than 300 scientific papers and 10 books at home and abroad. He Liang He Li science and technology progress award, Natural Science Award, who contribution award and other 18 awards. He is currently the director of Hongtao laboratory and doctoral supervisor of Institute of viral disease control and prevention of China Center for Disease Control and prevention, honorary president of Institute of life science and Bioengineering, Beijing Jiaotong University, and director of Institute of genetic engineering; he is also a professor of Peking Union Medical College and chairman of medical Committee of Pacific Association of Sciences.

• 

  Zhang Xiumei

  Professor and doctoral supervisor of Shandong University. He is the executive director of Chinese society of pharmacology, chairman of teaching and popular science committee of Chinese Pharmacology Society, vice chairman of marine pharmacology Committee of Chinese Pharmacology Society, national licensed pharmacist qualification certification expert of State Food and drug administration, expert of medical accident technical appraisal committee of Chinese Medical Association, member of Standing Committee of Shandong Provincial People's Congress and pharmacology of Medical College of Shandong University He is the director of the Institute, chairman of Shandong Pharmacology Society, chairman of pharmacology Committee of Shandong Pharmaceutical Association, chairman of Shandong ADR expert advisory committee, expert of medical accident technical appraisal committee of Shandong Medical Association, and new drug evaluation expert of Shandong Province. He has been supported by the State Council for study abroad twice (from April 1987 to September 1989 and from June 1998 to June 1999) to work as a post doctoral research, senior visiting scholar and visiting professor in the medical school of Virginia State University. Taking the lead, it has undertaken more than 10 national, provincial and ministerial, department and bureau level research projects on cardio cerebrovascular, neurology, traditional Chinese medicine and other new drugs, and more than 40 other cooperative projects, horizontal projects and new drug research. As the leader, he won 8 first, second and third prizes for scientific research progress at provincial, ministerial and departmental levels. He has published more than 70 papers in international and domestic journals, 28 books edited by chief editor, deputy editor, chief examiner and participant, and more than 20 textbooks of various types at all levels.

• 

  Xu Conggao

  He was born in Laizhou City, Shandong Province in May 1945. He graduated from the medical department of Shandong Medical College in 1969. He obtained a master's degree in hematology in 1981. From 1981 to 1983, he studied hematology in the medical school of Northwestern University in the United States. After returning to China, he has worked in Qilu Hospital of Shandong University. He served as the chief physician, second-class Professor, doctoral supervisor and top-notch scientific and technological talents of Shandong University. He was also the deputy leader of anemia blood group of Hematology branch of Chinese Medical Association, chairman of Analytical Cytology society of Shandong Medical Association, honorary chairman of Hematology Committee of Shandong Medical Association, Chinese Journal of Hematology, leukemia lymphoma and Chinese tumor Journal of prevention and treatment, etc. Professor Xu Conggao has presided over and completed more than 10 national and provincial scientific research projects, and has won one first prize of science and technology progress award of Shandong Provincial Science and Technology Commission, one second prize of science and technology progress award of Shandong Provincial Science and Technology Commission, one third prize of science and Technology Progress Award of Ministry of health and seven provincial science and Technology Awards (the first place).

• 

  Chang Xiaotian

  He is a doctor, researcher, distinguished expert of Taishan Scholars in Shandong Province, and a leader of Shandong medical and health system discipline. He has the title of director of medical research center of Shandong Qianfoshan hospital, director of Central Laboratory of Shandong Qianfoshan hospital, and assistant to the president of Shandong Qianfoshan hospital. He studied abroad in 1993, studied and worked in biomedical fields in Japan and the United States, and once served as the Research Institute of physics and chemistry in Japan Researcher, Institute of genomics research center. After returning to China, he was the first to obtain 1 National 973 project, 3 general projects of NSFC, 6 provincial key scientific and technological research projects and NSFC; a total of 40 SCI papers were published, including 26 first author and corresponding author (the highest citation rate of a single article was 55 times), SCI cited more than 1000 times (the highest citation rate of a single article was 222), and 30 Chinese core journals; 12 invention patents were authorized first (including 1 international one) ）。

• 

  Jiang Guosheng

  He is a doctor of medicine, a researcher, a leading talent of the national "ten thousand talents program", a distinguished expert of Taishan Scholars in Shandong Province, and deputy director of the Institute of basic medicine of Shandong Academy of Medical Sciences; his main social posts are: doctoral supervisor of Shandong University, member of American Society of Hematology, executive director of Chinese society of immunology, director of Chinese society of medical biotechnology, and blood immunology branch of Chinese society of immunology He is a member of the board of directors of Shandong society of immunology, Secretary General of Shandong society of medical biotechnology, chairman of Shandong Provincial Committee of hematoimmunology, vice chairman of Microbiology and Immunology branch of Shandong Medical Association, executive director of Shandong society of Biochemistry and molecular biology, director of Shandong society of experimental animals, executive director of Shandong society of toxicology, and chairman of Shandong Anti-Cancer Association Executive director. He has won 5 second prizes of science and technology progress, 3 third prizes of natural sciences of Shandong Province and 2 third prizes of science and technology progress of Shandong Province. He was the first to apply for 5 national invention patents.

• 

  He Jinsheng

  Professor, doctoral supervisor, doctor of medicine, executive vice director of Institute of biology, School of science, Beijing Jiaotong University, lifelong member of Chinese society of immunology, editorial board member of International Journal of immunology. He graduated from the Department of clinical medicine of Anhui Medical University with a bachelor's degree in July 1986, a master's degree in medicine in July 1994, and a doctor's degree in virus disease prevention and control center of China (formerly Chinese Academy of Preventive Medical Sciences) in July 2001. From October 2004 to October 2005, he was a visiting scholar at McLaughlin life medicine research center, University of Toronto, Canada.

• 

  Huang Jiaqiang

  Doctor of medicine, 1997, Tongji Medical College, Huazhong University of science and Technology (formerly Tongji Medical University). Professor, Department of immunology, Peking University, 1997-1999; postdoctoral, Department of immunology, Peking University. From 1999 to 2004, NIH, NCI, lab of molecular immunomodulation; visiting scholar (1999-2001), scientist (2001-2004, basic research program, SAIC Frederick). Professor, assistant researcher, Johns Hopkins University School of medicine, 2004-2006. 2006-2011 sabiosciences, USA; senior scientist. Professor, Institute of life science and Bioengineering, School of science, Beijing Jiaotong University, 2011. Since 2013, visiting researcher of NCI Cancer & amp; inflammation program, USA.

• 

  Cao Chuanhai

  Professor, research assistant, Department of Microbiology and immunology, University of South Florida, assistant professor, gene therapy center, University of South Florida, USA. He graduated from Shenyang Medical College in 1986. In February 2002, he was promoted to research assistant of Department of Microbiology and Immunology by University of South Florida. At the same time, he also served as assistant professor of gene therapy center and senior researcher of gene therapy research center and Florida Institute of Alzheimer's disease. He mainly engaged in the research of human hepatitis C antigen and applied computer technology The surface antigen active region of hepatitis C gene was simulated and analyzed. The results showed that NS3, NS4 and C regions of the gene had high antigenicity. The research results were published in international journals and conferences, and were highly valued by the international industry.

• 

  Xing Yanqiu

  Professor of Shandong University, doctor of medicine, doctoral supervisor, young and middle-aged key scientific and technological talents of Shandong health system. Harvard University Students (postdoctoral) returned to China. From May 2001 to August 2003, he was selected by the National Scholarship Council to carry out postdoctoral research in Tufts University and Harvard Medical School. As the main researcher, he participated in two NIH grants (hl-67970, ag-00837) and one project funded by American Heart Association (AHA 2002established inves tigator award grant). The research direction is the mechanism of myocardial energy metabolism, involving a series of molecular biological and biochemical methods and technologies, such as transgenic technology, protein expression and purification, high-pressure liquid chromatography spectroscopy and radionuclide technology. During his study in the United States, he published three papers in SCI as the first author and three papers as the second author. He made a speech at the 75th annual Heart Disease Conference in 2002. In September 2003, he returned home and was promoted to associate professor and professor. At present, he is responsible for one project of national natural fund of China, two projects of science and Technology Department of Shandong Province, and three projects of Shandong Provincial Department of health. As the main participant, he won one second prize of national science and Technology Progress Award and one third prize of Shandong science and Technology Progress Award in 2005, and one first prize of Shandong science and Technology Progress Award in 2000, and published more than 20 papers in domestic and foreign magazines as the first author.

• 

  Zhang Wenhua

  Professor of Shandong University, doctor of medicine, doctoral supervisor. His doctoral dissertation is "basic research on gene therapy of Parkinson's disease", which was awarded as excellent doctoral dissertation of Shandong Province. From February 2002 to February 2004, and from September 2008 to April 2011, he carried out two postdoctoral studies in Harvard Medical School. He has independently completed four NIH funded projects (ninds-ns41635, ns39324) and one project funded by American ALS Disease Association (2002 the ALS disease) Society of America, published 6 papers in the first-class professional journals in the United States, and made a speech at the 2003 American annual meeting of neuroscience. He won the 2008 American International Young neurosurgery physician Award for his outstanding work. At present, he continues to study the mechanism of ALS and cerebral ischemia-reperfusion injury and its drug treatment in China. We have completed one project of NSFC, Shandong provincial fund for Distinguished Youth, Ministry of education's start-up fund for returned overseas students, and Shandong provincial natural fund respectively, and responsible for one project of Shandong Provincial Science and technology department. As the main participant or as the main participant, he was nominated by the Ministry of education with one second prize of national science and technology progress award, two second prize of Shandong Province Science and technology progress award, and one third prize of Shandong Province Science and technology progress award, and was awarded the young and middle-aged key scientific and technological talents of Shandong health system. More than 50 papers have been published by the first author in domestic and foreign journals, and 15 papers have been cited by SCI for more than 500 times.

• 

  Wang Yong

  Deputy general manager and chief technology officer of Shandong Xinchuang Biotechnology Co., Ltd., director of tumor bacterial therapy experimental center, senior engineer, Jinan high-level talents, German returned students. November 2011 to may 2013, Bonn, Germany He studied in the Institute of Biochemistry and molecular biology of University. After returning home, he has been engaged in the research and development of bacterial targeted oncolytic drugs. He presided over the world's first class 1 anti-tumor drug, Clostridium gloeosporioides spore freeze-dried powder for injection, which was the first in the world. The research results filled in the gap at home and abroad, making China in the international leading position in the field of bacterial oncolysis. On September 10, 2020, the project obtained the clinical trial license of nmpa biological products class 1 new drug (cxsl2000177), and became the world's first bacterial oncolytic drug with clinical trial license. In recent three years, he has presided over one national major new drug creation science and technology major project, one Shandong Province small and medium-sized enterprise innovation competition action plan, and as the technical director, he has organized and implemented one major new drug creation project of Shandong Province major scientific and technological innovation project and one science and technology development plan of Jinan City. From 2018 to 2020, 6 SCI papers have been published and 6 invention patents have been authorized. It won one first prize of provincial and ministerial level scientific and technological innovation achievements. He won the honorary titles of "Shandong May 1st Labor Medal", "Jinan May 1st Labor Medal" and "the most beautiful scientific and technological worker" of Jinan high tech Zone in 2019.

• 

  Yu Na

  Deputy general manager and deputy director of science and technology, director of cell and regenerative medicine experimental center, senior engineer and doctor of Shandong Xinchuang Biotechnology Co., Ltd. He graduated from Northeast Agricultural University in 2014. After graduation, he has been engaged in gene detection, animal model preparation, and cellular immunotherapy. He is proficient in gene cloning, vector construction, gene knockout and expression, protein purification, enzymatic properties, biodiversity analysis and other aspects, as well as cell culture, differentiation, cryopreservation, and optimization of cryopreservation conditions The preparation and detection of various tumor animal models and cell models, as well as the corresponding pharmacodynamic studies. He has won the May 1st Labor award of Shandong Pharmaceutical and chemical industry system, published more than 10 papers, and 3 papers were included in SCI.